Single Dose rATG for Renal Allograft Rejection

Status unconfirmed · Phase 4

Conditions studied: Acute (Cellular) Renal Allograft Rejection

In brief

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter.Single large-doses of rATG have been shown to have equivalent safety and efficacy profile compared to the standard daily protocol when used as an induction agent but there are no reported experiences of its use for rejection treatment. Plan to study a single-dose rATG infusion compared to standard rATG administration including correlation to length of hospital stay and hospital costs.

Key facts

Study ID

NCT02102854

Run by

The Methodist Hospital Research Institute

People needed

30

Starts

2014-03-01

Expected to finish

2021-10-01

Last updated by the study team

2020-09-03

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects aged 18 years or older
• Experiencing a biopsy-proven acute rejection episode which:
• will require the use of rATG based on severity, or
• is exhibiting resistance to corticosteroid treatment, defined as failure of the serum creatinine to decrease after at least 3 days of corticosteroid treatment (≥200 mg/day of methylprednisolone or equivalent)

You may not qualify if…

• Patients with known severe allergy to antithymocyte globulin or rabbits
• Rejection episode requiring the use of therapeutic plasma exchange immediately subsequent to rATG administration
• Currently receiving any investigational drug or treatments

Where it is running

• Houston Methodist Hospital — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.